1.	Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-4697, SWOG-E4697, E4697, NCT00005034
2.	Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-99-C-0137, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903
3.	Phase I/II Randomized Study of PR1 Leukemia Peptide Vaccine and Montanide ISA-51 in Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: MDA-DM-97325, NCI-T98-0017, NCT00004918, T98-0017
4.	Phase I/II Study of Human Alpha Fetoprotein Peptide Immunization in HLA-A*0201 Positive Patients With Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: UCLA-9905003, NCI-H00-0053, NCT00005629
5.	Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma (Phase I Closed to Accrual as of 3/29/06) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-03-C-0162, NCI-5855, 5855, NCT00062036
6.	Phase I/II Randomized Study of Vaccine Comprising Multiple Synthetic Melanoma Peptides, Montanide ISA-51, and Sargramostim (GM-CSF) in Patients With Stage IIIB, IIIC, or IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-MEL-41, UVACC-28502, UVACC-HIC-10464, NCT00089219
7.	Phase I/II Study of Adjuvant Vaccine Therapy Comprising Either Epstein-Barr Virus-Encoded Latent Membrane Protein (LMP)-2: 340-349 Peptide or LMP-2: 419-427 Peptide Emulsified in Montanide ISA-51 or Observation Alone in Patients With Anaplastic Nasopharyngeal Carcinoma at High Risk for Recurrence Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-04-CC-0118, NCT00112541
8.	Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-HIC-11491, Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
9.	Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: LUD2003-007, NCT00145158
10.	Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 20 to 80 Sponsor: Other Protocol IDs: FPCR1R2-2, NCT00655785
11.	Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0118, NCI-T97-0009, T97-0009
12.	Phase II Study of Immunization with Immunodominant Tyrosinase and gp100 Peptides in Patients With Recurrent or Refractory Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-98-C-0022, NCI-T97-0088, T97-0088, NCT00019383
13.	Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-98-C-0023, NCI-T97-0089, T97-0089
14.	Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: NCI-98-C-0040, NCI-T97-0092, T97-0092, NCT00019396
15.	Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002) Phase: Phase II Type: Treatment Status: Closed Age: 18-79 Sponsor: NCI Protocol IDs: UVACC-HIC-7621, UVA-HIC-7621, NCI-G98-1389, NCT00003222
16.	Phase II Randomized Study of Vaccine Comprising Tyrosinase Peptide and gp100 Antigen With Montanide ISA-51 Alone or With Sargramostim (GM-CSF) in Patients with Resectable Stage IIA or IIB Melanoma (Summary Last Modified 11/2001) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: LAC-USC-10M971, LAC-USC-FDR001101, NCI-T97-0100, NCT00003274, T97-0100
17.	Phase II Study of Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide Alone or in Conjunction With Interleukin-2 in Patients With Metastatic Melanoma Who Have Failed Prior Vaccine Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-98-C-0095, NCI-T98-0012, T98-0012, NCT00019487
18.	Phase II Randomized Study of a Vaccine Combining Tyrosinase and gp100 Peptides Emulsified with Montanide ISA-51 With or Without Interleukin-12 for Patients with Resected Stage III or IV Melanoma (Summary Last Modified 03/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, NCT00003339, T97-0099
19.	Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-98012, NCI-T97-0110, NCT00003362, T97-0110
20.	Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-98-C-0142, NCI-T98-0036, T98-0036
21.	Phase II Randomized Pilot Study of Vaccine Therapy With Tumor-Specific Mutated von Hippel-Lindau Peptides in Patients With Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-98-C-0139, NCI-T97-0081, T97-0081, NCT00019526
22.	Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High-Dose Interleukin-2 in HLA-A2.1-Positive Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: CWG-UIC-T98-0027, NCI-T98-0027, NCT00003568, T98-0027
23.	Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0092, NCI-T99-0033, T99-0033, NCT00019721
24.	Phase II Randomized Study of Mutated gp100 Melanoma Vaccine in HLA-A2-Positive Patients With at Least 1 mm Melanoma on Initial Biopsy Phase: Phase II Type: Treatment Status: Completed Age: Over 16 Sponsor: NCI Protocol IDs: PPMC-IRB-99-9, NCI-T98-0081, NCT00003895, T98-0081
25.	Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994